218 related articles for article (PubMed ID: 27540317)
1. Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives.
Bayanzay K; Alzoebie L
J Blood Med; 2016; 7():159-69. PubMed ID: 27540317
[TBL] [Abstract][Full Text] [Related]
2. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
3. Current recommendations for chelation for transfusion-dependent thalassemia.
Kwiatkowski JL
Ann N Y Acad Sci; 2016 Mar; 1368(1):107-14. PubMed ID: 27186943
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
5. Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.
Veríssimo MP; Loggetto SR; Fabron Junior A; Baldanzi GR; Hamerschlak N; Fernandes JL; Araujo Ada S; Lobo CL; Fertrin KY; Berdoukas VA; Galanello R
Rev Bras Hematol Hemoter; 2013; 35(6):428-34. PubMed ID: 24478610
[TBL] [Abstract][Full Text] [Related]
6. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
[TBL] [Abstract][Full Text] [Related]
7. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.
Elalfy MS; Adly A; Awad H; Tarif Salam M; Berdoukas V; Tricta F
Am J Hematol; 2018 Feb; 93(2):262-268. PubMed ID: 29119631
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.
Hagag AA; Elfaragy MS; Elrifaey SM; Abd El-Lateef AE
Infect Disord Drug Targets; 2015; 15(3):189-95. PubMed ID: 26239735
[TBL] [Abstract][Full Text] [Related]
10. Management of iron overload in hemoglobinopathies.
Allali S; de Montalembert M; Brousse V; Chalumeau M; Karim Z
Transfus Clin Biol; 2017 Sep; 24(3):223-226. PubMed ID: 28673501
[TBL] [Abstract][Full Text] [Related]
11. Iron overload in thalassemia: different organs at different rates.
Taher AT; Saliba AN
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
[TBL] [Abstract][Full Text] [Related]
12. Iron and oxidative stress in cardiomyopathy in thalassemia.
Berdoukas V; Coates TD; Cabantchik ZI
Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
[TBL] [Abstract][Full Text] [Related]
13. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
14. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
16. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
17. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
18. Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior.
Ansari S; Azarkeivan A; Miri-Aliabad G; Yousefian S; Rostami T
Caspian J Intern Med; 2017; 8(3):159-164. PubMed ID: 28932366
[TBL] [Abstract][Full Text] [Related]
19. [Therapeuetic management of patients with thalassemia major].
Thuret I
Bull Soc Pathol Exot; 2001 May; 94(2):95-7. PubMed ID: 11475036
[TBL] [Abstract][Full Text] [Related]
20. Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients.
Bordbar M; Haghpanah S; Zekavat OR; Saki F; Bazrafshan A; Bozorgi H
Expert Rev Hematol; 2019 Nov; 12(11):997-1003. PubMed ID: 31486684
[No Abstract] [Full Text] [Related]
[Next] [New Search]
